December 18, 2025
NetraMark Holdings Inc.
ISIN: CA64119M1059
NetraMark Delivers Transformational Quarter of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award Secured TORONTO, ON, December 18, 2025 – NetraMark Holdings Inc. (the...
Read more >>NetraMark Achieves Major FDA Milestone
TORONTO, ON, December 15, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials...
Read more >NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
TORONTO, ON, December 8, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials...
Read more >NetraMark Signs Four New Contracts with a Leading Global Pharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, ON, November 18, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered...
Read more >